Genmab A (GMAB) Other Non-Current Liabilities (2019 - 2026)
Genmab A's (GMAB) quarterly Other Non-Current Liabilities came in at $4.0 in Q3 2020, down 100.0% YoY from $1.9 million in Q4 2019, and up 100.0% on a QoQ basis from $2.0 in Q4 2019.
Genmab A (GMAB) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 2 years of Other Non-Current Liabilities data on file, last reported at $4.0 in Q3 2020.
- Quarterly Other Non-Current Liabilities fell 100.0% year-over-year to $4.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $4.0 (down 100.0% YoY) and the FY2019 annual result came in at $2.0, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $4.0 in Q3 2020, from $2.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.9 million in Q3 2019 to a low of $2.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 861.00 Mn |
| Dec 31, 2025 | 1.07 Bn |
| Sep 30, 2025 | 602.00 Mn |
| Jun 30, 2025 | 567.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 489.00 Mn |
| Sep 30, 2020 | 4.00 |
| Dec 31, 2019 | 2.00 |
| Sep 30, 2019 | 1.86 Mn |